💸 The Tape

Seven weeks ago, Georgia had the least-utilized medical cannabis program in the United States. As of March 2026, the state counted roughly 34,500 registered patients against a population of 11.3 million — an adoption rate under 0.31%, dead last nationally and not particularly close. For a decade Georgia ran what everyone including the operators called the "low THC oil program," a name that told patients exactly how little they should expect.

Then SB 220 happened, and the numbers stopped behaving.

The Patient Curve

Senate Bill 220 — the Putting Georgia's Patients First Act — was signed by Gov. Brian Kemp on May 12 and took effect July 1, 2026. The registry response has been the steepest in the program's history:

• Late June: 36,595 patients

• July 1: roughly 36,700

• Early August: 44,854 to 44,889

• Mid-August: north of 45,000

That's roughly 22–23% growth in a single month, and about 32% since the beginning of June. More than 8,000 net new patients in a program that took ten years to reach 34,500. State data showed more than twice as many registrations in the first three weeks post-expansion as in the prior three-week period.

The mechanics behind the surge are worth understanding, because they're structural rather than promotional. SB 220 did four things at once. It added lupus, HIV and inflammatory bowel disease as qualifying conditions, bringing the state to 18 total. It stripped the "severe or end-stage" requirement from conditions including cancer, multiple sclerosis and Parkinson's — which had been forcing physicians to tell patients to come back when they were sicker. It legalized vaporization for patients 21 and older, adding flower and vape cartridges to a menu previously limited to oils, tinctures, capsules, lozenges, topicals and patches. And it replaced the 5% THC potency cap with a possession-based limit of 12,000 milligrams.

Smoking remains prohibited. Flower is sold prepackaged for vaporization, which is a distinction Georgia takes more seriously in statute than patients likely do in practice.

Gary Long, CEO of Botanical Sciences, has predicted the expansion could triple patient counts by mid-2027. At the current run rate that's not an aggressive call — it's arithmetic. Sustaining even half the July pace puts Georgia through 100,000 patients inside twelve months.

Is Product Selling Out?

Here's where the reporting gets thinner than the demand data, and it's worth being precise rather than dramatic.

What's confirmed: operators reported record sales following the July 1 launch. Trulieve ran launch-day events across all six of its Georgia dispensaries and is supplying more than a dozen independent pharmacies, with plans to expand that channel. Botanical Sciences is opening a sixth dispensary in Augusta. Fine Fettle's Macon facility represents a $40 million-plus investment across more than 100,000 square feet.

What's not confirmed: I have not seen credible reporting of sustained, statewide stockouts. Anyone telling you Georgia shelves are bare is extrapolating.

But the structural setup is genuinely tight, and here's why. Georgia's supply side is capped at six production licenses, 15 retail licenses and one independent testing lab. On June 30, the installed inventory of flower and vape product in the state was effectively zero — those categories were illegal. Cultivation and packaging cycles for new formats run months, not weeks. Into that, the state added 8,000+ patients whose primary interest is precisely the products that didn't exist. Vape cartridges in particular can be produced from existing oil stock relatively fast; whole flower cannot.

The expected pattern is therefore SKU-level intermittency rather than systemic shortage — specific strains and formats going out of stock at specific locations, restocks moving quickly, and allocation tension between company-owned dispensaries and the pharmacy channel. Any operator claiming perfectly smooth supply through a category launch of this speed is describing a plan, not a quarter.

The license mechanism adds a clock. Every 10,000 new patients unlocks an additional retail license. Georgia has already tripped that threshold once since June. If Long's tripling forecast lands, the state adds several more — meaning the current six-producer oligopoly gets diluted precisely as it's proving out demand. Incumbents have roughly a year of structural advantage to convert into market share.

The Delivery Wildcard

The Georgia Access to Medical Cannabis Commission is now proposing rules allowing direct-to-patient delivery — including via USPS, FedEx and UPS. Executive Director Andrew Turnage framed it as a geography problem: patients in parts of the state travel two hours or more past mountains, rivers and lakes to reach a dispensary. The proposed rules require certified mail or equivalent tracked service, restricted delivery, and a signature from the patient, caregiver or healthcare-institution employee, with proof logged in the state tracking system immediately.

The stated legal basis is the Trump administration's April rescheduling order, under which Acting AG Todd Blanche moved state-licensed medical cannabis to Schedule III. Turnage explicitly cited leveraging that authority. GMCC takes public comment September 16 and votes September 30.

Whether USPS, FedEx and UPS actually participate is an open question — none responded to press inquiries, and Georgia has been here before, having drawn a DEA warning to state pharmacies in 2023. But it's an intelligible bet on a state where Schedule III already reshaped the retail map, allowing DEA-registered independent pharmacies to dispense.

The Read

Georgia went from the least-penetrated medical program in America to arguably its fastest-growing in six weeks, on a supply base of six producers and 15 retail licenses that was sized for the old regime. Demand is verified. Supply strain is structurally probable but not yet documented — flag it as a question for operators, not a finding.

If delivery clears in September, the practical addressable market expands again without a single new dispensary opening. Watch the registry through Q4. At this trajectory, "tripling by mid-2027" is the conservative case.

📈 Dog Walkers

$CURLF ( ▼ 1.37% ) Formalizes The $ACB ( ▼ 2.17% ) Bid

Curaleaf (TSX: CURA / OTCQX: CURLF) has formally commenced its hostile take-over bid for Aurora Cannabis, taking the proposal directly to shareholders after what it characterizes as a board that wouldn't return the call.

The terms: 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash per Aurora share — implied consideration of US$4.00 based on Curaleaf's US$9.39 close on August 10. Against Aurora's unaffected 30-day VWAP of US$2.75, that's a 45% premium. Strip out Aurora's US$109 million in cash (US$1.62 per share) and the ex-cash premium jumps to 110%, or 127% measured against the July 7 close when Curaleaf sent its initial letter of intent.

There's a US$5.00 cap price, triggered if Curaleaf's 20-day VWAP exceeds C$17.05. The offer expires December 1, 2026, with no financing condition and no due diligence condition — the latter by necessity, since Curaleaf built the whole proposal off public filings.

The Bear Case Curaleaf Is Making

The circular reads less like a merger document and more like a short thesis with a bid attached.

Boris Jordan's central argument is that Aurora's board is anchored to a 2025 share price that no longer describes the business. He points to reduced Canadian medical reimbursement rates and the cancellation of German medical reimbursement — hitting Aurora in its two most important markets simultaneously — plus consecutive quarters of underperformance and continued dilution from an ATM program issuing below the offer price.

Then the numbers, which land harder. Aurora's balance sheet as of March 31 shows C$7.0 billion of share capital against a C$6.4 billion accumulated deficit, roughly 72% of which is impairment of acquired businesses. Between fiscal 2020 and fiscal 2026, Aurora recognized approximately C$4.65 billion of impairments in continuing operations.

And the line that will get quoted most: Aurora has booked inventory impairments and "business transformation" costs in fiscal 2024, 2025, 2026 and again in Q1 fiscal 2027 — nearly C$150 million excluded from adjusted results. Curaleaf's observation is difficult to argue with. Charges incurred four years running are not non-recurring.

Valuation-wise, Curaleaf pegs the offer at 12.0x CY2026E adjusted EBITDA — 68% above the 7.1x Canadian peer average and 58% above Aurora's own 7.6x. Aurora's own FY2027 guidance contemplates lower revenue and lower EBITDA than the year just closed, which is an awkward thing to defend a "too low" valuation against.

The Combined Entity

Pro forma: more than US$1.5 billion LTM revenue, roughly US$350 million LTM adjusted EBITDA, and a market cap above US$3.0 billion. Curaleaf claims at least US$40 million in annual cost synergies across overhead, procurement, supply chain and international infrastructure, and brings ~US$145 million of trailing operating cash flow.

The operational pitch has teeth. Curaleaf runs roughly 472,000 square feet of canopy, and says it has raised yields per square foot nearly 90% while cutting cost per gram nearly 50% since Q1 2024. Its cultivation footprint is three times Aurora's, with production capacity nearly six times.

What Actually Matters Now

The consideration is mostly Curaleaf paper. The US$4.00 headline holds only if CURLF holds US$9.39. Aurora's board doesn't need to argue the offer is cheap — it needs to argue the currency is soft. Expect exactly that.

The tender bar is high. Curaleaf needs more than 50% of independent shares and 66⅔% fully diluted. Hostile bids die on that second number regularly.

Aurora formed a Special Committee on August 11, and Jordan's response was pointed: a one-line reply, he said, isn't engagement — it's a dismissal.

Aurora's formal recommendation is the next real catalyst. Watch whether the rights plan gets deployed.

📺 Trade To Black

Cannabis Industry Hits a Turning Point | TTB Presented by Flowhub

• Texas hemp politics turn combustible — Democrat James Talarico is hammering Republican Senate candidate and current AG Ken Paxton for dodging a direct question about the state's THC ban. A video of the exchange posted to X has already drawn national attention.

• Joe Rogan enters the chat — Democrats are amplifying the podcaster's warning that an aggressive THC crackdown could flip Texas blue, turning a regulatory fight into a statewide electoral one.

• Segment #1: Vireo Growth's breakout quarter — Sammy Armenia, Director of Capital Markets at Vireo (CSE: VREO / OTCQX: VREOF), walks through Q2 2026: $209.3M GAAP revenue, up 335% YoY, $41.5M adjusted EBITDA, near-breakeven net income, and $122.7M in cash. With Hawthorne, Eaze and Bridgewell absorbed and more deals pending, Vireo is building toward top-tier national scale.

• Segment #2: The rescheduling clock starts — Michael Bronstein of the American Trade Association for Cannabis & Hemp unpacks today's federal briefing deadline. The ALJ shifts into the administrative phase, and Bronstein gives a realistic read on when feedback from the summer hearings actually lands.